File No. 333-110040
                                                      Filed under Rule 424(b)(3)


               PROSPECTUS SUPPLEMENT NO. 2 DATED NOVEMBER 29, 2004


          To the Prospectus dated October 28, 2003, as supplemented by
               Prospectus Supplement No. 1 dated November 6, 2003



                               CYTOGEN CORPORATION

                         ------------------------------

     This prospectus supplement  supplements,  and should be read in conjunction
with,  the  prospectus,  as  previously  supplemented,  dated  October 28, 2003,
relating to $60,000,000 in shares of our common stock that we may offer and sell
from time to time. We will receive all of the proceeds from any shares sold. The
prospectus  was  filed as part of our  registration  statement  on Form S-3 (No.
333-110040).

                         ------------------------------

     INVESTING  IN OUR COMMON  STOCK  INVOLVES A HIGH DEGREE OF RISK.  SEE "RISK
FACTORS" BEGINNING ON PAGE 4 OF THE PROSPECTUS.

                         ------------------------------

     NEITHER THE  SECURITIES AND EXCHANGE  COMMISSION  NOR ANY STATE  SECURITIES
COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THIS
PROSPECTUS  SUPPLEMENT  IS  TRUTHFUL  OR  COMPLETE.  ANY  REPRESENTATION  TO THE
CONTRARY IS A CRIMINAL OFFENSE.

                         ------------------------------

     No dealer,  salesperson or any other person has been authorized to give any
information  or make  any  representations  not  contained  in  this  prospectus
supplement or the prospectus, as previously supplemented, and, if given or made,
the  information  or  representations  must not be relied  upon as  having  been
authorized by us. This prospectus  supplement and the prospectus,  as previously
supplemented,  do not constitute an offer to sell, or a solicitation of an offer
to buy, any securities to any person in any jurisdiction  where such an offer or
solicitation  would  be  unlawful.  Neither  the  delivery  of  this  prospectus
supplement  or the  prospectus,  as previously  supplemented,  nor any sale made
hereunder or thereunder shall,  under any  circumstance,  create any implication
that the  information  contained  herein or  therein  is  correct as of any time
subsequent to the date hereof.

Issuance of Common Stock

     On November 19, 2004, we entered into Addendum No. 2 to the Stock  Exchange
Agreement  dated as of June 15,  1999,  as  amended,  among the  Company and the
stockholders




and  debtholders of Prostagen,  Inc. The Addendum was effective  immediately and
provides  that we shall deliver such number of shares of our common stock having
a value equal to $500,000  within ten business days of the date of the Addendum.
We are hereby  registering 50,000 shares of our common stock to be issued to the
stockholders and debtholders of Prostagen in connection with Addendum No. 2. The
prospectus  provides for the sale of up to $60,000,000  in registered  shares of
our common stock.


                                November 29, 2004